A Phase 2 interventional study of Lurasidone 20 mg and Lurasidone 40 mg in Schizophrenia, sponsored by Sumitomo Pharma America, Inc.. Completed at 26 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-04-17.
Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing lurasidone in Schizophrenia — none open to participants now, none under way, none of them phase 3. lurasidone · Schizophrenia.
Among the 39 studies testing lurasidone in Schizophrenia, this one is the 24th largest by enrollment, is one of 2 that started in 2002, is one of 5 in phase 2, and was the 1st registered.
3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.
Browse Schizophrenia studies →None of the 39 studies testing lurasidone in Schizophrenia is open now. The open studies under Schizophrenia, anywhere →
lurasidone: first FDA approval 2010 (LATUDA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2002.
This study's enrollment of 98 is above the median of 71 across 2,947 interventional studies indexed under Schizophrenia.
Median enrollment 149 across the 39 interventional studies. Of the 38 that completed or were terminated, 27 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 39 have an industry lead sponsor. The 10 most frequent:
This study is registered under Sumitomo Pharma America, Inc., one of the names counted as Sumitomo Pharma Co., Ltd.. Under that name alone:
Sumitomo Pharma America, Inc. is the lead sponsor of 181 studies on the registry; 5 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 21 (64%) have results posted.
40 studies in Schizophrenia by Sumitomo Pharma Co., Ltd.: none open now, none under way, none of them phase 3. Of 40 finished, 28 (70%) have results posted.
Among the 40 studies in Schizophrenia by Sumitomo Pharma Co., Ltd., this one is the 25th largest by enrollment of the 39 interventional ones that give a count, is one of 2 that started in 2002, is one of 4 in phase 2, and was the 1st registered.
Sumitomo Pharma Co., Ltd.’s Schizophrenia studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 39 studies testing lurasidone in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sumitomo Pharma Co., Ltd.’s 40 in Schizophrenia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the long-term safety of SM-13496 in patients with schizophrenia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Lurasidone 20 mg oral tablet
Drug: Lurasidone 20 mg
Lurasidone 40 mg oral tablet
Drug: Lurasidone 40 mg
Lurasidone 80mg oral tablet
Drug: Lurasidone 80mg
Lurasidone 20mg oral tablet taken once daily for 6-months
Lurasidone 40mg oral tablets taken once daily
Lurasidone 80mg oral tablet taken once daily
Number of Participants With Adverse Events
The primary objective of this 6-month open-label study was to evaluate the safety of 3 doses of lurasidone.
Time frame: 6-months
| Milestone | Lurasidone 20 mg | Lurasidone 40 mg | Lurasidone 80mg |
|---|---|---|---|
| Started | 32 | 33 | 33 |
| Completed | 13 | 19 | 11 |
| Not completed | 19 | 14 | 22 |
The primary objective of this 6-month open-label study was to evaluate the safety of 3 doses of lurasidone.
| participants | Lurasidone 20 mg | Lurasidone 40 mg | Lurasidone 80mg |
|---|---|---|---|
| Number of Participants With Adverse Events | 19 ± 7.8 | 22 ± 12.4 | 18 ± 10.7 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lurasidone 20 mg | — | 3/32 (9.4%) | 19/32 (59.4%) |
| Lurasidone 40 mg | — | 6/33 (18.2%) | 22/33 (66.7%) |
| Lurasidone 80mg | — | 3/33 (9.1%) | 18/33 (54.5%) |
| Event | Lurasidone 20 mg | Lurasidone 40 mg | Lurasidone 80mg |
|---|---|---|---|
| Sinus tachycardiaCardiac disorders | 3/32 | 6/6 | 3/3 |
| SchizophreniaPsychiatric disorders | 2/32 | 4/33 | 1/33 |
| Suicidal IdeationPsychiatric disorders | 1/32 | 0/33 | 1/33 |
| FallInjury, poisoning and procedural complications | 0/32 | 1/33 | 0/33 |
| Lower Limb FractureInjury, poisoning and procedural complications | 0/32 | 1/33 | 0/33 |
| Pelvic FractureInjury, poisoning and procedural complications | 0/32 | 1/33 | 0/33 |
| HypokalaemiaMetabolism and nutrition disorders | 0/32 | 1/33 | 0/33 |
| Suicidal BehaviorPsychiatric disorders | 0/32 | 1/33 | 1/33 |
| Endotracheal IntubationSurgical and medical procedures | 0/32 | 1/33 | 0/33 |
| Event | Lurasidone 20 mg | Lurasidone 40 mg | Lurasidone 80mg |
|---|---|---|---|
| DizzinessNervous system disorders | 2/32 | 6/33 | 1/33 |
| HeadacheNervous system disorders | 5/32 | 5/33 | 5/33 |
| NasopharyngitisInfections and infestations | 3/32 | 4/33 | 0/33 |
| SedationNervous system disorders | 0/32 | 4/33 | 1/33 |
| DepressionPsychiatric disorders | 1/32 | 0/33 | 4/33 |
| VomitingGastrointestinal disorders | 3/32 | 2/33 | 3/33 |
| Upper Respiratory Tract InfectionInfections and infestations | 3/32 | 1/33 | 1/33 |
| InsomniaPsychiatric disorders | 3/32 | 1/33 | 2/33 |
| NauseaGastrointestinal disorders | 1/32 | 3/33 | 2/33 |
| ToothacheGastrointestinal disorders | 1/32 | 3/33 | 2/33 |
| Age, Continuous(years) | Lurasidone 20 mg | Lurasidone 40 mg | Lurasidone 80mg | Total |
|---|---|---|---|---|
| Mean | 40.8 ± 7.8 | 42.2 ± 12.4 | 40.8 ± 10.7 | 41.3 ± 10.4 |
| Sex: Female, Male(Participants) | Lurasidone 20 mg | Lurasidone 40 mg | Lurasidone 80mg | Total |
|---|---|---|---|---|
| Female | 11 | 12 | 5 | 28 |
| Male | 21 | 21 | 28 | 70 |
| Region of Enrollment(participants) | Lurasidone 20 mg | Lurasidone 40 mg | Lurasidone 80mg | Total |
|---|---|---|---|---|
| United States | 32 | 33 | 33 | 98 |
The record gives a start of Sep 2002, a primary completion of Nov 2003 and a completion of Nov 2003. It does not say whether these dates are actual or estimated.
Results were first posted in May 2011, 7 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lurasidone
Sumitomo Pharma America, Inc. →